Regeneron and Sanofi recently announced the preliminary results from the Phase II portion of an ongoing Phase II/III tri...
Award-winning digital patient recruitment Platform GeoMap Clinical has announced the Patient Enrollment Guarantee for sp...
BioNTech and Pfizer Inc. have disclosed additional details of their collaboration to advance candidates from BioNTech&rs...
Leading Australian CRO Avance Clinical on 3 April 2020 detailed the top reasons it's APAC biotechs selected Australia fo...
The Asia-Pacific (APAC) has emerged as the most prominent region for conducting clinical trials, accounting for over 40%...
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced on 2 April 2020 that it has appointed US-base...
"Spain and Norway are ready to enrol their patients for COVID-19 clinical trial", announces Dr Tedros Adhanom Ghebreyesu...
Asia-Pacific's largest specialist biotech CRO Novotech has been selected as a finalist in two categories for the Citelin...
Australian CRO Avance Clinical has said that Australia’s fast regulatory approval environment, key opinion leader ...
SGX-listed Singapore eDevelopment Ltd has announced that its wholly-owned U.S. biomedical subsidiary Impact BioMedical, ...
Award-winning global leader in digital patient recruitment GeoMap Clinical by TrialWire announced on 11 March 2020 that ...
Asia-Pacific’s largest specialist biotech CRO Novotech has been selected for the Komipharm International clin...
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for bio...
US based AVROBIO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic...
PPD, Inc. ( PPD ) has expanded its China operations and leadership team to provide more international and Chin...
Genome & Company, a clinical-stage biotechnology company based in Seongnam, Republic of Korea, has announced th...
Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrou...
CStone Pharmaceuticals has announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Co...
